New anticancer agents: Recent developments in tumor therapy

Anticancer Research

Volumn 32, Issue 7, 2012, Pages 2999-3005

  Ali, Riyasat ^a   Mirza, Zeenat ^b   Ashraf, Ghulam M D ^b   Kamal, Mohammad Amjad ^b   Ansari, Shakeel Ahmed ^b   Damanhouri, Ghazi Abdullah ^b   Abuzenadah, Adel Mohammad ^b   Chaudhary, Adeel Ga ^b   Sheikh, Ishfaq Ahmed ^b  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Natural products; New anticancer agents; Plant derived chemicals; Review

Indexed keywords

ANTINEOPLASTIC AGENT; AURANTIIN; BAICALIN; CAPECITABINE; CATECHIN; CURCUMIN; EPIGALLOCATECHIN GALLATE; GEMCITABINE; GENISTEIN; GREEN TEA EXTRACT; IRIDOID; LUTEOLIN; METHYLEUGENOL; NAVELBINE; PROCYANIDIN; QUERCETIN; RESVERATROL; RUTOSIDE; SOYASAPOGENOL A; SOYASAPOGENOL B; TERAMEPROCOL; TERREFURANOSE; TERREQUINONE A; THEAFLAVIN; THYMOL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; VINDESINE; VINFLUNINE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; BLADDER CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER THERAPY; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL GROWTH; CELL KILLING; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CONCENTRATION (PARAMETERS); CRYSTALLIZATION; CYTOSTASIS; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG EFFICACY; ENVIRONMENTAL STRESS; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HYDROPHOBICITY; LUNG NON SMALL CELL CANCER; MITOSIS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TRANSITIONAL CELL CARCINOMA;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL AGENTS; FLAVONOIDS; HUMANS; PLANT EXTRACTS; SAPONINS; VINCA ALKALOIDS;

EID: 84865682929     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. Siegel R, Naishadham D and Jemal A: Cancer Statistics. CA Cancer J Clin 62: 10-29, 2012.
2. Boyle P: The globalisation of cancer. Lancet 368: 629-630, 2006.
3. Vella N: Genetic profiling and ovarian cancer therapy. Mol Med Rep 4: 771-777, 2011.
4. Schwartsmann G: Marine organisms as a source of new anticancer agents. Lancet Oncol 2: 221-225, 2001.
5. Bravo L: Polyphenols: chemistry, dietary sources, metabolism, and nutritional significance. Nutr Rev 56: 317-333, 1998.
6. Ramos S: Effects of dietary flavonoids on apoptotic pathways related to cancer chemoprevention. J Nutr Biochem 18: 427-442, 2007.
7. Ramos S: Cancer chemoprevention and chemotherapy: dietary polyphenols and signalling pathways. Mol Nutr Food Res 52: 507-526, 2008.
8. Pan MH and Ho CT: Chemopreventive effects of natural dietary compounds on cancer development. Chem Soc Rev 37: 2558- 2574, 2008.
9. Chen C and Kong AN: Dietary chemopreventive compounds and ARE/EpRE signaling. Free Radic Biol Med 36: 1505-1516, 2004.
10. Vauzour D, Rodriguez-Mateos A, Corona G, Oruna-Concha MJ and Spencer JPE: Polyphenols and human health: prevention of disease and mechanisms of action. Nutrients 2: 1106-1131, 2010.
11. Fang JY and Richardson BC: The MAPK signalling pathways and colorectal cancer. Lancet Oncol 6: 322-327, 2005.
12. Wang W, Wang X, Peng L, Deng Q, Liang Y, Qing H and Jiang B: CD24-dependent MAPK pathway activation is required for colorectal cancer cell proliferation. Cancer Sci 101: 112-119, 2010.
13. Corona G, Spencer JP and Dessi MA: Extra virgin olive oil phenolics: absorption, metabolism, and biological activities in the GI tract. Toxicol Ind Health 25: 285-293, 2009.
14. Sebolt-Leopold JS and Herrera R: Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 4: 937-947, 2004.
15. Gosse F, Guyot S, Roussi S, Lobstein A, Fischer B, Seiler N and Raul F: Chemopreventive properties of apple procyanidins on human colon cancer-derived metastatic SW620 cells and in a rat model of colon carcinogenesis. Carcinogenesis 26: 1291-1295, 2005.
16. Corona G, Deiana M, Incani A, Vauzour D, Dessi MA and Spencer JP: Inhibition of p38/CREB phosphorylation and COX-2 expression by olive oil polyphenols underlies their antiproliferative effects. Biochem Biophys Res Commun 362: 606-611, 2007.
17. Yu R, Jiao JJ, Duh JL, Gudehithlu K, Tan TH and Kong AN: Activation of mitogen-activated protein kinases by green tea polyphenols: potential signaling pathways in the regulation of antioxidant-responsive element-mediated phase II enzyme gene expression. Carcinogenesis 18: 451-456, 1997.
18. Chen C, Yu R, Owuor ED and Kong AN: Activation of antioxidant-response element (ARE), mitogen-activated protein kinases (MAPKs) and caspases by major green tea polyphenol components during cell survival and death. Arch Pharm Res 23: 605-612, 2000.
19. Spencer JP, Rice-Evans C and Williams RJ: Modulation of pro-survival Akt/protein kinase B and ERK1/2 signaling cascades by quercetin and its in vivo metabolites underlie their action on neuronal viability. J Biol Chem 278: 34783-34793, 2003.
20. Chung JH, Han JH, Hwang EJ, Seo JY, Cho KH, Kim KH, Youn JI and Eun HC: Dual mechanisms of green tea extract (EGCG)- induced cell survival in human epidermal keratinocytes. FASEB J 17: 1913-1915, 2003.
21. Surh YJ: Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 3: 768-780, 2003.
22. Surh YJ: NF-kappa B and Nrf2 as potential chemopreventive targets of some anti-inflammatory and antioxidative phytonutrients with anti-inflammatory and antioxidative activities. Asia Pac J Clin Nutr 17: 269-272, 2008.
23. Gopalakrishnan A and Tony Kong AN: Anticarcinogenesis by dietary phytochemicals: cytoprotection by Nrf2 in normal cells and cytotoxicity by modulation of transcription factors NF-kappa B and AP-1 in abnormal cancer cells. Food Chem Toxicol 46: 1257-1270, 2008.
24. Hayakawa S, Saeki K, Sazuka M, Suzuki Y, Shoji Y, Ohta T, Kaji K, Yuo A and Isemura M: Apoptosis induction by epigallocatechin gallate involves its binding to Fas. Biochem Biophys Res Commun 285: 1102-1106, 2001.
25. Kawai K, Tsuno NH, Kitayama J, Okaji Y, Yazawa K, Asakage M, Sasaki S, Watanabe T, Takahashi K and Nagawa H: Epigallocatechin gallate induces apoptosis of monocytes. J Allergy Clin Immunol 115: 186-191, 2005.
26. Nishikawa T, Nakajima T, Moriguchi M, Jo M, Sekoguchi S, Ishii M, Takashima H, Katagishi T, Kimura H, Minami M, Itoh Y, Kagawa K and Okanoue T: A green tea polyphenol, epigalo-catechin- 3-gallate, induces apoptosis of human hepatocellular carcinoma, possibly through inhibition of BCL-2 family proteins. J Hepatol 44: 1074-1082, 2006.
27. Yokoyama M, Noguchi M, Nakao Y, Pater A and Iwasaka T: The tea polyphenol, (-)-epigallocatechin gallate effects on growth, apoptosis, and telomerase activity in cervical cell lines. Gynecol Oncol 92: 197-204, 2004
28. Mertens-Talcott SU and Percival SS: Ellagic acid and quercetin interact synergistically with resveratrol in the induction of apoptosis and cause transient cell cycle arrest in human leukemia cells. Cancer Lett 218: 141-151, 2005.
29. Mujtaba T and Dou QP: Black tea polyphenols inhibit tumor proteasome activity. In Vivo 26: 197-202, 2012.
30. Mu LN, Zhou XF, Ding BG, Wang RH, Zhang ZF, Chen CW, Wei GR, Zhou XM, Jiang QW and Yu SZ: A case control study on drinking green tea and decreasing risk of cancers in the alimentarycanal among cigarette smokers and alcohol drinkers. Zhonghua Liu Xing Bing Xue Za Zhi 24: 192-195, 2003.
31. Wang M, Guo C and Li M: A case control study on the dietary risk factors of upper digestive tract cancer. Zhonghua Liu Xing Bing Xue Za Zhi 20: 95-97, 1999.
32. Sasazuki S, Inoue M, Miura T, Iwasaki M and Tsugane S: Plasma tea polyphenols and gastric cancer risk: a case control study nested in a large population-based prospective study in Japan. Cancer Epidemiol Biomarkers Prev 17: 343-351, 2008.
33. Wu AH, Tseng CC, Van Den Berg D and Yu MC: Tea intake, COMT genotype, and breast cancer in Asian-American women. Cancer Res 63: 7526-7529, 2003.
34. Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G and Corti A: Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res 66: 1234-1240, 2006.
35. Hostettmann K and Marston A: Saponins. Cambridge: Cambridge University Press, 1995.
36. Oleszak W and Marston A: Saponins in Feedstuff and Medicinal Plants. Dordrecht: Kluwer Academic Publishers, 2000.
37. Gurfinkel DM and Rao AV: Soyasaponins: the relationship between chemical structure and colon anticarcinogenic activity. Nutr Cancer 47: 24-33, 2003.
38. Rao AV and Gurfinkel DM: The bioactivity of saponins: triterpenoid and steroidal glycosides. Drug Metabol Drug Interact 17: 211-235, 2000.
39. Bombardelli E: Special soy extracts containing isoflavone glycosides and saponins. US Patent -492921, 2000.
40. Kim HJ, Song JY, Park HJ, Park H-K, Yun DH and Chung JH: Naringin protects against rotenone-induced apoptosis in human neuroblastoma SHSY5Y cells. Korean J Physiol Pharmacol 13: 281-285, 2009.
41. Deng W, Fang X and Wu J: Flavonoids function as antioxidants: by scavenging reactive oxygen species or by chelating iron? Radiat Phys Chem 50: 271-276, 1997.
42. Ueda S, Nakamura H, Masutani H, Sasada T, Takabayashi A, Yamaoka Y and Yodoi J: Baicalin induces apoptosis via mitochondrial pathway as prooxidant. Mol Immunol 38: 781-791, 2002.
43. Kinjo J, Morito K, Tsuchihashi R, Hirose T, Aomori T and Okawa M: Examination for estrogenic activities of soyasaponin I and related compounds. Nat Med 58: 193-197, 2004.
44. Pettit GR, Doubek DL, Herald DL, Delbert L, Numata A and Takahashi C: Isolation and structure of cytotoxic steroidal saponins from the African medicinal plant Balanites aegyptica. J Nat Prod 54: 1491-1502, 1991.
45. Gnoula C, Megalizzi V, De Neve N, Sauvage S, Ribaucour F and Guissou P: Balanitin-6 and -7: diosgenyl saponins isolated from Balanites aegyptiaca Del. display significant antitumor activity in vitro and in vivo. Int J Oncol 32: 5-15, 2008.
46. Bianchi E and Cole JR: Antitumor agents from Agave schottii. J Pharm Sci 58: 589-591, 1969.
47. Kaminobe F, Kameoka H, Nakamura S and Shioyama M: Carcinogenic substance and production thereof Yucca schidigera extract with carcinostatic effect, and preparation method thereof. Japanese Patent 04145029A 19920519, 2002.
48. Kim SW, Park SK, Kang SL, Kang HC, Oh HJ, Bae CY and Bae DH: Hypocholesterolemic property of Yucca schidigera and Quillaja saponaria extracts in human body. Arch Pharm Res 26: 1042-1046, 2003.
49. Olas B, Wachowicz B, Stochmal A and Oleszek W: Anti-platelet effects of different phenolic compounds from Yucca schidigera Roezl. bark. Platelets 13: 167-173, 2002.
50. Vandepapeliere P: Novel vaccine compositions that induce immune response. PCT Int. Appl. WO 2007068907 A2 20070621, 2007.
51. Beit-Yannai E, Ben-Shabat S, Goldschmidt N, Chapagain BP, Liu RH and Wiesman Z: Antiproliferative activity of steroidal saponins from Balanites aegyptiaca - an in vitro study. Phytochem Lett 4: 43-47, 2011.
52. Peng SF, Lu S, Liu SLE and Xing H: An anticancer preparation containing at least two kinds of plant extract. Canadian Patent 101171020A 20080430, 2008.
53. Noble RL, Beer CT and Cutts JH: Role of chance observations in chemotherapy: Vinca rosea. Ann NY Acad Sci 76: 882-894, 1958.
54. Fahy J, Hellier P, Breillout F and Bailly C: Vinflunine: discovery and synthesis of a novel microtubule inhibitor. Semin Oncol 35: S3-5, 2008.
55. Jordan MA, Himes RH and Wilson L: Comparison of the effects of vinblastine, vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro. Cancer Res 45: 2741-2747, 1985.
56. Dumontet C and Jordan MA: Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 9: 790-803, 2010.
57. Toso RJ, Jordan MA, Farrell KW, Matsumoto B and Wilson L: Kinetic stabilization of microtubule dynamic instability in vitro by vinblastine. Biochemistry 32: 1285-1293, 1993.
58. Ngan VK, Bellman K, Hill BT, Wilson L and Jordan MA: Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine. Mol Pharmacol 60: 225-232, 2001.
59. Kruczynski A, Barret JM, Etievánt C, Colpaert F, Fahy J and Hill BT: Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid. Biochem Pharmacol 55: 635-648, 1998.
60. Etievant C, Barret JM, Kruczynski A, Perrin D and Hill BT: Vinflunine (20′,20′-difluoro-3′,4′-dihydrovinorelbine), a novel Vinca alkaloid, which participates in P-glycoprotein (Pgp)- mediated multidrug resistance in vivo and in vitro . Invest New Drugs 16: 3-17, 1998.
61. Kruczynski A, Etievánt C, Perrin D, Chansard N, Duflos A and Hill BT: Characterization of cell death induced by vinflunine, the most recent Vinca alkaloid in clinical development. Br J Cancer 86: 143-150, 2002.
62. Holwell SE, Hill BT and Bibby MC: Antivascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model. Br J Cancer 84: 290-295, 2001.
63. Lavielle G, Hautefaye P, Schaeffer C, Boutin JA, Cudennec CA and Pierré A: New alpha-amino phosphonic acid derivatives of vinblastine: chemistry and antitumor activity. J Med Chem 3: 1998-2003, 1991.
64. Kruczynski A, Poli M, Dossi R, Chazottes E, Berrichon G, Ricome C, Giavazzi R, Hill BT and Taraboletti G: Antiangiogenic, vascular-disrupting and anti-metastatic activities of vinflunine, the latest vinca alkaloid in clinical development. Eur J Cancer 42: 2821-2832, 2006.
65. Bonfil RD, Russo DM, Binda MM, Delgado FM and Vincenti M: Higher antitumor activity of vinflunine than vinorelbine against an orthotopic murine model of transitional cell carcinoma of the bladder. Urol Oncol 7: 159-166, 2002.
66. Culine S, Theodore C, De Santis M, Bui B, Demkow T, Lorenz J, Rolland F, Delgado FM, Longerey B and James N: A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer 94: 1395-1401, 2006 .
67. Vaughn DJ, Srinivas S, Stadler WM, Pili R, Petrylak D, Sternberg CN, Smith DC, Ringuette S, de Wit E, Pautret V and George C: Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study. Cancer 115: 4110-4117, 2009.
68. Tournoux-Facon C, Senellart H, Lemarie E, Tourani JM, Favrel S, Pouget JC, Pinel MC and Bennouna J: Phase I and pharmacokinetic study of IV vinflunine in combination with gemcitabine for treatment of advanced non-small cell lung cancer in chemonaive patients. J Thorac Oncol 6: 1247-1253, 2011.
69. Campone M, Isambert N, Bourbouloux E, Roché H, Bonneterre J, Milano G and Fumoleau P: A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes. Cancer Chemother Pharmacol 69: 871-879, 2012.
70. Chen Q: Nordihydroguaiaretic acid analogs: their chemical synthesis and biological activities. Curr Top Med Chem 9: 1636-1659, 2009.
71. Medina-Holgu'n AL, Holgu'n FO, Micheletto S, Goehle S, Simon JA and O'Connell MA: Chemotypic variation of essential oils in the medicinal plant Anemopsis californica. Phytochemistry 69: 919-927, 2008.
72. Xu Y, Burns AM, McLaughlin SP and Gunatilaka AA: Iridoids as cell migration inhibitors from Valeriana sorbifolia. 19th Rocky Mountain Regional Meeting of the American Chemical Society, Tucson, AZ, USA, 14-18 October; abstract no. RM-155, 2006.
73. Jia K: New anticancer medicine. Faming Zhuanli Ahenging Gongkai Shuomingshu. Chinese Patent 1535712A 20041013, 2004.
74. Badria FA, Ameen M and Akl MR: Evaluation of cytotoxic compounds from Calligonum comosum L. growing in Egypt. Z Naturforsch [C] 62: 656-660, 2007.
75. Jayatilake G, Freeberg DR, Liu Z, Richheimer SL, Blake NME and Bailey DT: Isolation and structures of avicins D and G: in vitro tumor-inhibitory saponins derived from Acacia victoriae . J Nat Prod 66: 779-783, 2003.
76. Abdelwahed A, Skandrani I, Kilani S, Neffati A, Ben Sghaier M and Bouhlel I: Mutagenic, antimutaganic, cytotoxic and apoptotic activities of extracts from Pituranthos tortuosus. Drug Chem Toxicol 31: 37-60, 2008.
77. Abdallah HM and Ezzat SM: Effect of the method of preparation on the composition and cytotoxic activity of the essential oil of Pituranthos tortuosus. J Biosci 66: 143-148, 2011.
78. Shen T, Wan W, Yuan H, Kong F, Guo H, Fan P and Lou H: Secondary metabolites from Conmmiphora opobalsamum and their antiproliferative effect on human prostate cancer cells. Phytochemistry 68: 1331-1337, 2007.
79. Al-Dabbas MM, Suganuma T, Kitiahara K, Hou DX and Fujii M: Cytotoxic, antioxidant and antibacterial activities of Varthemia iphionoides Boiss extracts. J Ethnopharmacol 108: 287-293, 2006.
80. Drissi A, Bennani H, Giton F, Charrouf Z, Fiet J and Adlouni A: Tocopherols and saponins derived from Argania spinosa extract. Antiproliferative effect on human prostate cancer. Cancer Invest 24: 588-592, 2006.
81. Bennani H, Drissi A, Giton F, Kheuang L, Fiet J and Adlouni A: Antiproliferative effect of polyphenols and sterols of virgin argan oil on human prostate cancer cell lines. Cancer Detect Prev 31: 64-69, 2007.
82. Kandouz M, Alachkar A, Zhang L, Dekhil H, Chehna F, Yasmeen A and Al Moustafa A-E: Teucrium polium plant extract inhibits cell invasion and motility of human prostate cancer cells via the restoration of the E-cadherin/catenin complex. J Ethnopharmacol 129: 410-415, 2010.
83. Rinehart KL: Antitumor compounds from tunicates. Med Res Rev 20: 1-27, 1999.
84. Segraves NL: Comparison of fascaplysin and related alkaloids: a study of structures, cytotoxicities, and sources. J Nat Prod 67: 783-792, 2004.
85. Donia M: Natural combinatorial peptide libraries in cyanobacterial symbionts of marine ascidians. Nat Chem Biol 2: 729-735, 2006.
86. Uddin MJ: Haterumaimides F-I, four new cytotoxic diterpene alkaloids from an ascidian Lissoclinum species. J Nat Prod 64: 1169-1173, 2001.
87. Uddin J: Cytotoxic labdane alkaloids from an ascidian Lissoclinum sp.: isolation, structure elucidation, and structure-activity relationship. Bioorg Med Chem 14: 6954-6961, 2006.
88. Malochet-Grivois C: Effects in vitro of two marine substances, chlorolissoclimide and dichlorolissoclimide, on a non-small-cell bronchopulmonary carcinoma line (NSCLC-N6). Anticancer Drug Des 7: 493-502, 1992.
89. Ogi T: Isolation of C11 cyclopentenones from two didemnid species, Lissoclinum sp. and Diplosoma sp. Mar. Drugs 7: 816-832, 2009.
90. Oda T: Cytotoxicity of lissoclibadins and lissoclinotoxins, isolated from a tropical ascidian Lissoclinum cf. badium, against human solid-tumor-derived cell lines. Biol Pharm Bull 30: 385-387, 2007.
91. Choi H: Tuberatolides, potent FXR antagonists from the Korean marine tunicate Botryllus tuberatus. J Nat Prod 74: 90-94, 2011.
92. Aiello A: New bioactive sulfated metabolites from the Mediterranean tunicate Sidnyum turbinatum. J Nat Prod 64: 219-221, 2011.
93. Garrido L: Haouamines A and B: a new class of alkaloids from the ascidian Aplidium haouarianum. J Org Chem 68: 293-299, 2003.